Dongkoo Bio&Pharma and D&D Pharmatech both contributed to a series A round for the neurologic disorder drug spinout from Johns Hopkins.

Neuraly, a US-based developer of therapies for neurologic disorders spun out from Johns Hopkins University, disclosed a $36m series A round on Wednesday.

The round featured pharmaceutical company Dongkoo Bio&Pharma and Parkinson’s disease drug developer D&D Pharmatech.

Smilegate Investment, InterVest, LB Investment, Magna Investment, Geon Investment, Octave Life Sciences and Maryland Venture Fund also contributed to the round, which followed $100,000 in debt financing in 2016, according to a securities filing.

Founded in 2016, Neuraly is working on neuroprotective agents…